ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

dapirolizumab pegol

Also written as “Dapirolizumab pegol (DZP)”, “DZP” and “CDP7657”.

Its studies are mostly in Lupus Erythematosus, Systemic, led by 2 companies.

Drug pageDapirolizumab pegol: every studyAll 8 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Feb 27, 20208 company-led studies, 3 open or runningNext primary completion: May 31, 2028 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
UCBits history only73 open or runningphase 3since Feb 27, 2020Mar 12, 2010May 31, 2028phase 3 · NCT06617325
Biogen10 open or runningphase 1since Sep 25, 2020Sep 25, 2020none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Biogen only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 25, 2020First study: phase 1 study in Healthy VolunteersFirst studyNCT04571424 · 33 enrolled · United States

TargetBeta

CD40LG →read by rule
“CD40 ligand inhibitor”ChEMBL 37, by rule

Other programs on CD40LG

ProgramCompanyFurthest phaseStudies
frexalimabSanofiphase 311
dazodalibepruleAmgenphase 39
tegoprubartruleeledon-pharmaceuticalsphase 38
ravagalimabruleAbbViephase 24
OPT101ruleop-t-llcphase 24
TNX-1500ruleTonix Pharmaceuticalsphase 11

Studies

The one study Biogen leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT04571424Healthy Volunteers · United States1CompletedApr 8, 202133

How it is read

Names in the registry

  • “Dapirolizumab pegol (DZP)”, 2 entries
  • “DZP”, 2 entries
  • “CDP7657”, 2 entries
  • “Dapirolizumab pegol”, 1 entry
  • “BIIB133 (Dapirolizumab pegol)”, 1 entry

Codes read as this program: CDP7657.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.